Proactive Investors - Run By Investors For Investors

Scancell inks collaboration deal with leading US lung cancer foundation

It is teaming up with the Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J Addario Lung Cancer Foundation.
Scancell inks collaboration deal with leading US lung cancer foundation
Lung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths

Scancell Holdings Plc (LON:SCLP) has inked a US collaboration deal with a leading lung cancer foundation that will accelerate the development of a ground-breaking immuno-oncology drug.

It is teaming up with the Addario Lung Cancer Medical Institute (ALCMI) and the Bonnie J Addario Lung Cancer Foundation to take its SCIB2 cancer vaccine in phase I/II clinical trials.

Patients with non-small cell lung cancer (NSCLC) will receive the treatment.

ALCMI will assist Scancell with the design and development of the study, which is set to get underway in 2018 and complete around 18 months later.

 “We have generated preclinical data that suggests that SCIB2 could be the ideal complement to existing and emerging checkpoint inhibitor therapies to treat NSCLC and so provide an effective new potential treatment option for patients with this devastating disease,” said Scancell CEO Richard Goodfellow.

Lung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths.

That’s more than breast, prostate and colon cancers combined. Around 228,000 people receive a cancer diagnosis in the US alone and more than 160,000 will not survive.

“This partnership enables us to access an important clinical programme that could also accelerate the development of this ground-breaking immunotherapy technology,” said ALCMI president Steven Young.

SCIB2 was developed using the company’s ImmunoBody cancer vaccine platform.

It is a new breed of immunotherapy treatment that stimulates the body’s own defences to potentially treat and prevent cancer.

The company recently successfully completed a Phase I/II clinical trial with SCIB1 in patients with melanoma.

“Immunotherapy has dramatically improved many patients' outcomes across various cancer types,” said Jacob Sands, assistant professor of medical oncology at the Lahey Hospital & Medical Center, one of the ALCMI member institutions.

“One of the next steps is how we can further enhance the immune response to cancer. Early clinical data on ImmunoBody suggests it is extremely well tolerated and may significantly improve outcomes, which would be ideal.

“I'm excited to work with Scancell and hopeful that we will take another important step in the fight against lung cancer.” 

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
Surgery
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use